Equity Profile

BBIO

BridgeBio Pharma, Inc.

Health CareBiotechnology$16.3B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

BridgeBio Pharma Misses on EPS, Stock Down 0.94%

Metric	Actual	Expected	Surprise
EPS	$-0.84	$-0.67	-19.32%
Revenue	—	$179M	—

management commentary, guidance changes, and full analysis available with Pro.

BridgeBio Pharma Misses on EPS, Stock Down 0.94%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.84	$-0.67	-19.32%
Revenue	—	$179M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

BridgeBio Pharma's earnings report showed a larger-than-expected loss per share, which contributed to a slight decline in the stock price. The lack of revenue data and guidance may leave investors uncertain about the company's future performance. The stock's reaction reflects cautious sentiment among investors following these results.

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.67

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$179M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers. With a market cap of $13 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs through innovative treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In the last quarter, BridgeBio reported an EPS of $-1.00, missing expectations by 34%. The stock saw a slight increase of 0.59% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect BridgeBio to report a loss of $-0.67 per share on revenues of $179 million for Q1-2026. The market is closely watching for any signs of improvement in financial performance.

Bull Case

If BridgeBio can exceed revenue expectations and show progress in its drug development pipeline, it could lead to a positive market reaction.

Bear Case

Conversely, if the company reports a larger loss than expected or fails to provide a clear path to profitability, it may face significant downward pressure on its stock.

Key Metrics to Watch

EPS

$-0.67

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$179M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its drug pipeline or upcoming trials?

Investors are keen to hear about advancements in the pipeline, which could impact future revenue and growth potential.

How does management plan to address the recent trend of EPS misses?

Understanding management's strategy to improve financial performance is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BridgeBio's pipeline to deliver unexpected positive results, which could lead to better-than-expected revenue.

Supporting Evidence

The options market is pricing an 8.62% move, suggesting higher volatility than historical averages.

BridgeBio's recent insider selling could indicate a lack of confidence in the near-term outlook, which contrasts with potential positive developments in the pipeline.

Key Risk

If the company announces significant progress in its clinical trials, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a pattern of missed earnings expectations, and investors are looking for signs of recovery.

Bull Confirmed If

A revenue figure exceeding $196 million would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.84 would reinforce the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.62%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±8.6% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

41.0%

Calls (24K)P/C Ratio: 1.11Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests the stock could rise by around 2.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 2.39%, reflecting ongoing concerns about the company's financial health.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials for key therapies.
2Any guidance on expected revenue growth for the upcoming quarters.
3Management's commentary on cost management and profitability strategies.
4Insights into market demand for existing and upcoming products.
5Responses to analyst questions regarding recent EPS misses.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

FANGReported

Diamondback Energy, Inc.

RecapView

May4

OSISReported

Company Snapshot

BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-0.67

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$179M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-3.09%

Avg Stock Reaction

+0.50%

Last Quarter Recap

In the last quarter, BridgeBio reported an EPS of $-1.00, missing expectations by 34%. The stock saw a slight increase of 0.59% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect BridgeBio to report a loss of $-0.67 per share on revenues of $179 million for Q1-2026. The market is closely watching for any signs of improvement in financial performance.

Bull Case

If BridgeBio can exceed revenue expectations and show progress in its drug development pipeline, it could lead to a positive market reaction.

Bear Case

Conversely, if the company reports a larger loss than expected or fails to provide a clear path to profitability, it may face significant downward pressure on its stock.

Key Metrics to Watch

EPS

$-0.67

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$179M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the company provide any updates on its drug pipeline or upcoming trials?

Investors are keen to hear about advancements in the pipeline, which could impact future revenue and growth potential.

How does management plan to address the recent trend of EPS misses?

Understanding management's strategy to improve financial performance is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BridgeBio's pipeline to deliver unexpected positive results, which could lead to better-than-expected revenue.

Supporting Evidence

The options market is pricing an 8.62% move, suggesting higher volatility than historical averages.

BridgeBio's recent insider selling could indicate a lack of confidence in the near-term outlook, which contrasts with potential positive developments in the pipeline.

Key Risk

If the company announces significant progress in its clinical trials, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a pattern of missed earnings expectations, and investors are looking for signs of recovery.

Bull Confirmed If

A revenue figure exceeding $196 million would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.84 would reinforce the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.62%

Historical Avg

±2.2%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±8.6% while BBIO has averaged ±2.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

41.0%

Calls (24K)P/C Ratio: 1.11Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BridgeBio beats expectations, history suggests the stock could rise by around 2.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 2.39%, reflecting ongoing concerns about the company's financial health.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

3 buys·0 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of clinical trials for key therapies.
2Any guidance on expected revenue growth for the upcoming quarters.
3Management's commentary on cost management and profitability strategies.
4Insights into market demand for existing and upcoming products.
5Responses to analyst questions regarding recent EPS misses.